SCHEMBL196197

SCHEMBL196197

C=CC(O)[CH]CCCC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11576921 0.76
SCHEMBL195475 0.74 GRIK1 (0.42)
SCHEMBL680154 0.74
SCHEMBL16287785 0.73
SCHEMBL3004862 0.73 PPARG (0.43)
SCHEMBL3004869 0.73 PPARG (0.43)
SCHEMBL12500474 0.72
SCHEMBL5318104 0.72
SCHEMBL289814 0.72
SCHEMBL5847747 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 604 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239786-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CANCER YALE UNIVERSITY 2024-07-18 US claimed
WO-2022221181-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CANCER YALE UNIVERSITY (US) 2022-10-20 WO claimed
US-7479526-B2 Hydroxy-functional binder components CYTEC SURFACE SPECIALTIES AUSTRIA GMBH (AT) 2009-01-20 US claimed
US-20060194922-A1 Hydroxy-functional binder components CYTEC SURFACE SPECIALTIES AUSTRIA GMBH (AT) 2006-08-31 US claimed
US-20240239786-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CANCER YALE UNIVERSITY 2024-07-18 US disclosed
EP-4373493-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH ENHANCED IMID ACTIVITY Nurix Therapeutics, Inc. (US) 2024-05-29 EP disclosed
EP-4370123-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH DIMINISHED IMID ACTIVITY Nurix Therapeutics, Inc. (US) 2024-05-22 EP disclosed
WO-2024086296-A1 COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K MEKANISTIC THERAPEUTICS LLC (US) 2024-04-25 WO disclosed
US-20240124475-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY NURIX THERAPEUTICS, INC. 2024-04-18 US disclosed
US-20240092766-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2024-03-21 US disclosed
EP-4334303-A1 COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE Nurix Therapeutics, Inc. (US) 2024-03-13 EP disclosed
EP-4334302-A1 COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE Nurix Therapeutics, Inc. (US) 2024-03-13 EP disclosed
EP-0499434-A1 Detergent compositions UNILEVER PLC (GB) 1992-08-19 EP disclosed
EP-0491532-A1 Detergent compositions UNILEVER PLC (GB) 1992-06-24 EP disclosed
EP-0491531-A1 Detergent compositions UNILEVER PLC (GB) 1992-06-24 EP disclosed
EP-0487262-A2 Detergent compositions UNILEVER PLC (GB) 1992-05-27 EP disclosed
US-3991080-A Prostaglandin intermediates HOFFMANN-LA ROCHE INC. (US) 1976-11-09 US disclosed
US-3975406-A Hexahydro-5-oxy-2-loweralkoxy-2H-cyclopenta[b]-furan-4-carbonitrile intermediates for prostaglandins MAYER HANS JOHANN 1976-08-17 US disclosed
US-3974185-A Hexahydro-cyclopentano[b]furans having a 2-C.tbd.C containing substituent in the 4-position HOFFMANN-LA ROCHE INC. (US) 1976-08-10 US disclosed
US-3970674-A Certain hexahydro-2-loweralkoxy-5-oxycyclopenta [b] furans containing an olefinic substituent in the 4-position HOFFMANN-LA ROCHE INC. (US) 1976-07-20 US disclosed